文献速递神经肿瘤脊柱脊髓外科

辅助放疗对脊髓低级别胶质瘤总生存期的影响:一项倾向性评分匹配分析

The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.
PubMed 文献 · J Neurooncol · 2024-11-11

该研究利用美国国家癌症数据库(NCDB)纳入552例脊髓低级别胶质瘤患者,比较单纯手术与手术联合辅助放疗的总生存期。倾向性评分匹配前放疗组死亡率显著更高,匹配后总生存期差异不再显著(p=0.11)。结论认为辅助放疗未带来显著总生存获益,初始死亡率差异主要源于放疗组病期更晚等混杂因素。

要点

  • 倾向性评分匹配后,辅助放疗与单纯手术的总生存期差异无统计学显著(p=0.11)。
  • 匹配前辅助放疗组死亡率显著更高,主要归因于该组病期更晚等混杂因素。
  • 辅助放疗组患者年龄更大(中位40.0岁 vs 24.0岁,p<0.001),WHO 2级肿瘤比例更高(p<0.001)。

核心结论

  • 本研究未发现辅助放疗对脊髓低级别胶质瘤(sLGG)有显著总生存获益。
  • 接受辅助放疗的患者初始死亡率更高,但该差异主要由放疗组病期更晚等混杂因素所致。

研究设计与样本

  • 研究使用美国国家癌症数据库(NCDB)这一大型全国性癌症登记库进行倾向性评分匹配分析。
  • 通过ICD-O-3组织学编码9382、9384、9400、9410、9411、9420、9421、9424、9425和9450及脊髓脑膜(C70.1)和脊髓(C72.0)拓扑编码识别病例,排除脊髓室管膜瘤。
  • 共纳入552例患者,单纯手术组440例,手术联合辅助放疗组156例,采用1:1倾向性评分匹配平衡队列后行Kaplan-Meier生存分析,主要结局为总生存期。

主要发现

  • 辅助放疗组患者显著更年长(中位年龄40.0岁 vs 24.0岁,p<0.001),WHO 2级肿瘤比例更高(p<0.001)。
  • 辅助放疗组接受辅助化疗的比例更高(23% vs 7%,p<0.001)。
  • 倾向性评分匹配前,辅助放疗组死亡率显著更高(p<0.0001)。
  • 倾向性评分匹配后,两组总生存期差异不再显著(p=0.11)。

临床怎么用

  • 原文结论未据此给出推荐,仅报告辅助放疗未显示显著总生存获益,初始死亡率差异主要归因于混杂因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Spinal low-grade gliomas (sLGGs) are a group of tumors that arise from glial cells in the spinal cord. Current evidence supporting the use of adjuvant radiotherapy for the management of sLGG is lacking. We hence aimed to compare overall survival rates in patients receiving surgery alone with those receiving surgery with adjuvant radiotherapy. METHODS: The NCDB, a large, nationwide, US-based cancer registry was used. Relevant cases were identified using the following ICD-O-3 histological codes: 9382, 9384, 9400, 9410, 9411, 9420, 9421, 9424, 9425, and 9450, along with the ICD-O-3 topographical codes for spinal meninges (C70.1) and spinal cord (C72.0), excluding spinal ependymomas. Overall survival was the primary outcome. Propensity score matching 1:1 was used to balance the cohorts prior to Kaplan-Meier survival analysis. RESULTS: A total of 552 patients were included in the study, with 440 in the surgery alone group and 156 in the surgery with adjuvant radiotherapy group. Patients in the surgery with adjuvant radiotherapy group were significantly older (median age 40.0 vs. 24.0 years, p < 0.001), and exhibited higher proportions of WHO grade 2 tumors (p < 0.001). Adjuvant chemotherapy was more frequently administered in the surgery with adjuvant radiotherapy group (23% vs. 7%, p < 0.001). Overall, adjuvant radiotherapy was not associated with improved survival, with a significantly higher mortality in the radiotherapy group before propensity score matching (p < 0.0001). After matching, the difference in overall survival was no longer significant (p = 0.11). CONCLUSION: This study found no significant overall survival benefit associated with the use of adjuvant radiotherapy for spinal low-grade gliomas (sLGG). Although patients who received adjuvant radiotherapy initially demonstrated higher mortality rates, this difference was largely due to confounding factors such as more advanced disease in this group.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. El-Hajj VG, Ranganathan S, Hoang H, et al. The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis. J Neurooncol. 2024. PMID: 39527384. doi:10.1007/s11060-024-04880-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。